Trusted Advice and Innovative Solutions
Pragmatically addressing your legal concerns similarly to in-house counsel, we prioritize your interests and maximize the value of your technology and intellectual property assets to enhance your business success.


Representative Matters
Advised European BioPharma company on territory specific license agreement worth up to $75 million
Advised biotech company on structuring of global license agreement with royalties and milestone payments in excess of $200 million.
Advised biotech company in its strategic collaboration to discover and develop therapeutic antibodies in oncology.
Advised specialty pharma company on a variety of partnering transactions in connection with its drug delivery platform technologies.
Advise biopharma company on the structuring of its supply chain and the negotiation of distribution and supply agreements for multiple oncology products.
Advised a global rare disease company on multiple license and collaboration agreements with international partners.
Advised an Asian biotech company in its collaboration to discover and develop targeted proteins for novel oncology targets.
Advised a U.S. company on its collaboration in connection with the development of a groundbreaking COVID-19 diagnostic
Advise pharma company in a research collaboration and license agreement valued at up to $150 million for the development and commercialization up to four products.
Advised a publicly traded European pharmaceutical company in a collaboration and option agreement with a potential total deal value over the course of the partnership of up to $400 million.
Represented VC funded biotech startup in an in-license of a monoclonal antibody and related intellectual property from a global company.
Served as outside general counsel to a variety of life science companies supporting them in all of their legal needs.
Represented a publicly traded diagnostics company in the commercialization of a technology platform for use in various diagnostic applications including structuring and negotiating research, development, license and supply agreements.
Represented a specialty pharmaceutical company in connection with all aspects of its commercialization activities including out-licensing, in-licensing and supply chain agreements.
Represented a publicly traded pharmaceutical company in a product development and licensing transaction worth over $200 million.
Represented multiple companies in sponsored research and clinical trial agreements with universities and other partners.
Represented a venture capital-backed company in a license and collaboration transaction involving its drug discovery platform.
Represented multiple pharmaceutical companies in connection with pre-clinical and clinical development activities including services agreements with CROs and supporting vendors, clinical study agreements and laboratory services agreements
Represented a medical device company in the licensing of a proprietary technology from a major research University.
Representative Matters
Advised European BioPharma company on territory specific license agreement worth up to $75 million
Advised biotech company on structuring of global license agreement with royalties and milestone payments in excess of $200 million.
Advised biotech company in its strategic collaboration to discover and develop therapeutic antibodies in oncology.
Advised specialty pharma company on a variety of partnering transactions in connection with its drug delivery platform technologies.
Advise biopharma company on the structuring of its supply chain and the negotiation of distribution and supply agreements for multiple oncology products.
Advised a global rare disease company on multiple license and collaboration agreements with international partners.
Advised an Asian biotech company in its collaboration to discover and develop targeted proteins for novel oncology targets.
Advised a U.S. company on its collaboration in connection with the development of a groundbreaking COVID-19 diagnostic
Advise pharma company in a research collaboration and license agreement valued at up to $150 million for the development and commercialization up to four products.
Advised a publicly traded European pharmaceutical company in a collaboration and option agreement with a potential total deal value over the course of the partnership of up to $400 million.
Represented VC funded biotech startup in an in-license of a monoclonal antibody and related intellectual property from a global company.
Served as outside general counsel to a variety of life science companies supporting them in all of their legal needs.
Represented a publicly traded diagnostics company in the commercialization of a technology platform for use in various diagnostic applications including structuring and negotiating research, development, license and supply agreements.
Represented a specialty pharmaceutical company in connection with all aspects of its commercialization activities including out-licensing, in-licensing and supply chain agreements.
Represented a publicly traded pharmaceutical company in a product development and licensing transaction worth over $200 million.
Represented multiple companies in sponsored research and clinical trial agreements with universities and other partners.
Represented a venture capital-backed company in a license and collaboration transaction involving its drug discovery platform.
Represented multiple pharmaceutical companies in connection with pre-clinical and clinical development activities including services agreements with CROs and supporting vendors, clinical study agreements and laboratory services agreements
Represented a medical device company in the licensing of a proprietary technology from a major research University.